MAPK14 and cancer: In summary, our results indicated that BX357664 is significantly downregulated in RCC and may serve as a potential tumor suppressor in RCC by inhibiting the TGF-β1/p38/HSP27 signaling pathway and by interfering with cancer invasion and metastasis in RCC.